- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05481528
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Study to Investigate the Safety and Pharmacokinetics of Single Ascending Supratherapeutic Doses of Elinzanetant in Healthy Participants
Researchers are looking for a better way to treat vasomotor symptoms, a condition of having hot flashes. The condition is caused by hormonal changes and occurs primarily in women, but can also affect men.
The study treatment, elinzanetant, is under development to treat symptoms caused by hormonal changes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.
Participants of this study will be healthy and will have no benefit from administration of elinzanetant. This study, however, will provide information on how to use it in people with vasomotor symptoms.
In previous studies, elinzanetant doses tested and resulting blood levels were close to the levels intended for treatment. However, in future use, it cannot always be ruled out that higher elinzanetant concentrations may occur in the blood if patients are taking certain other drugs at the same time, or take more than the recommended dose of the drug.
The main purpose of this study is to learn how safe elinzanetant is when higher doses than normally used are given compared to placebo in healthy participants. A placebo is a treatment that looks like a medicine but does not have any medicine in it.
To answer this, researchers will compare the number of participants who have medical problems after taking elinzanetant to those treated with placebo. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.
The study consists of two parts. In part 1, the participants will either take a single dose of elinzanetant or placebo by mouth dependent on the treatment group. Four different increasing doses of elinzanetant will be tested.
Participants in dose group 1 and 4 will participate in part 2. About 8 days after treatment in part 1, the participants will receive a single dose of moxifloxacin and a single dose of placebo as tablet by mouth 5 days apart. Whether the participant starts with moxifloxacin or placebo is decided by chance. Moxifloxacin is used to make sure that certain changes in heart rhythm can be detected in the study.
Each participant will be in the study for about 6 weeks including 1 treatment day (part 1) or for about 8 weeks including 3 treatment days (part 1 & 2). Participants of part 1 will stay in-house for 7 days. Participants of part 2 will stay in-house for another 9 days. The in-house phase starts two days before intake of the study treatment. In addition, one visit before and one visit after the in-house phase to the study site is planned.
During the study, the study team will:
- Do physical examinations
- Check vital signs
- Take blood and urine samples
- Examine the participants' heart health using electrocardiogram (ECG)
- Ask the participants questions about their mood and about sleepiness.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Bayern
-
Neu-Ulm, Bayern, Germany, 89231
- NUVISAN GmbH Neu-Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, blood pressure, pulse rate, respiratory rate, body temperature and electrocardiogram (ECG).
- Body weight of at least 50 kg.
- Body mass index (BMI) within the range 18.0 to 30.0 kg/m^2 (inclusive).
- Male subjects of reproductive potential must agree to use a condom (with or without spermicide) when sexually active with a female partner and refrain from donating sperm. This applies for the time period between the signing of the informed consent form (ICF) until 5 days after the last administration of study intervention. Female partners of childbearing potential of male subjects do not need to follow special precautions.
- Women of childbearing potential will have to use a highly effective non-hormonal contraception when having sexual intercourse with a male partner from signing of the ICF until 5 days after the last administration of study intervention.
Exclusion Criteria:
- Any clinically relevant abnormal findings in medical history and physical examination. Including: History or evidence of any clinically relevant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other clinically relevant disease, as judged by the investigator; Diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention will not be normal.
- Known or suspected hypersensitivity or allergy to the study interventions or other fluoroquinolone products.
- Relevant diseases within the last 4 weeks prior to the first administration of study intervention, including febrile illness.
- Contraindications for the use of moxifloxacin, including: Medical history of seizures or psychiatric disorders, myasthenia gravis, severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN; also known as Lyell's syndrome), Stevens Johnson syndrome (SJS) and Acute Generalized Exanthematous Pustulosis (AGEP), glucose-6-phosphate dehydrogenase deficiency.
- Pregnant or breastfeeding women.
- Tendency for vasovagal reactions or history of syncope.
- Use of mild, moderate, or strong CYP3A4 and P-gp inhibitors from 2 weeks, and use of CYP3A4 and P-gp inducers from 4 weeks prior to the first administration of study intervention.
- Use of drugs which may affect absorption and systemic administration of any broad-spectrum antibiotic within 1 week prior to first administration of study intervention.
- Use of drugs which may affect absorption by increasing the gastrointestinal pH e.g. proton pump inhibitors from 2 weeks prior to first administration of study intervention.
- Use of any herbal products or St. John's wort within 4 weeks prior to the first administration of study intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1 - Dose group 1
Single oral dose of elinzanetant or placebo.
|
Single oral dose of placebo
Single oral dose of elinzanetant
|
Experimental: Part 1 - Dose group 2
Single oral dose of elinzanetant or placebo
|
Single oral dose of placebo
Single oral dose of elinzanetant
|
Experimental: Part 1 - Dose group 3
Single oral dose of elinzanetant or placebo
|
Single oral dose of placebo
Single oral dose of elinzanetant
|
Experimental: Part 1 - Dose group 4
Single oral dose of elinzanetant or placebo
|
Single oral dose of placebo
Single oral dose of elinzanetant
|
Experimental: Part 2: Moxifloxacin - Placebo
Participants of Dose Groups 1 and 4 will receive a single dose of moxifloxacin in Period 1 and a single dose of placebo in Period 2.
|
Single oral dose of placebo
Single oral dose of 400 mg moxifloxacin
|
Experimental: Part 2: Placebo - Moxifloxacin
Participants of Dose Groups 1 and 4 will receive a single dose of placebo in Period 1 and a single dose of moxifloxacin in Period 2.
|
Single oral dose of placebo
Single oral dose of 400 mg moxifloxacin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs related to elinzanetant
Time Frame: After first application of study intervention until 20 days after last application of study intervention
|
After first application of study intervention until 20 days after last application of study intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC (if AUC cannot be determined reliably in all subjects, AUC(0-tlast) will be used instead) of elinzanetant
Time Frame: 0 - 96 hours post-dose
|
AUC stands for area under the concentration versus time curve from zero to infinity
|
0 - 96 hours post-dose
|
Cmax of elinzanetant
Time Frame: 0 - 96 hours post-dose
|
Cmax stands for maximum observed concentration
|
0 - 96 hours post-dose
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21670
- 2022-000056-11 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hot Flashes
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
University of California, San FranciscoCompleted
-
University of California, San FranciscoCompleted
-
AmgenCompleted
-
Alison Huang, MDNational Institute on Aging (NIA)Completed
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTreatment of Menopausal Hot FlashesUnited States
-
Donesta BioscienceSynteractHCRCompleted
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedHot Flashes | Hot FlushesUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedFever, Sweats, and Hot FlashesUnited States
-
University of PennsylvaniaForest LaboratoriesCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States